SUPPLEMENTAL DIGITAL CONTENT
SDC Table 1. Characteristics of study population for IMPDH I variant (rs2278293)
Characteristic CC n=314 CT+TT n=612 P value
Geographic origin Europe North America
292 (93%)
22 (7%)
537 (88%)
75 (12%)
0.014
Transplant year 1993‐2000 2001‐2007
111 (35%) 203 (65%)
243 (40%) 369 (60%)
0.20
Transplant number First transplant Retransplant
259 (82%)
55 (18%)
513 (84%)
99 (16%)
0.60
Recipient gender Female Male
120 (38%) 194 (62%)
231 (38%) 381 (62%)
0.89
Donor gendera Female Male
126 (40%) 187 (60%)
251 (41%) 361 (59%)
0.82
Recipient age (y) 49.5 ± 13.0 48.3 ± 13.7 0.19
Donor age (y) 45.9 ± 16.5 45.1 ± 17.2 0.45
Cold ischaemia time (h) 18.4 ± 7.9 17.8 ± 6.4 0.57
HLA‐A+B+DR mismatches
0‐1
2‐4
5‐6
40 (13%) 225 (72%)
49 (16%)
74 (12%) 443 (72%)
95 (16%)
0.96
Panel reactive antibodiesa 0‐10%
11‐50%
>50%
205 (72%)
49 (17%) 30 (11%)
399 (70%) 111 (19%) 63 (11%)
0.72
Original disease diabetes 24 (8%) 52 (8%) 0.65
Initial immunosuppression Cyclosporine
Tacrolimus
Cyclosporine patients Steroids
No steroids Tacrolimus patients
Steroids No steroids Depleting antibody Non‐depleting antibody No induction
186 (59%) 128 (41%)
179 (96%)
7 (4%) 125 (98%)
3 (2%) 36 (11%) 62 (20%) 216 (69%)
398 (65%) 214 (35%)
387 (97%)
11 (3%) 212 (99%)
2 (1%) 74 (12%) 135 (22%) 403 (66%)
0.08
0.51
0.29
0.65
Chronic immunosuppression
At 1 year post‐transplant Cyclosporine patients
Steroids
MMF (mg/kg/day) Tacrolimus patients
Steroids
MMF (mg/kg/day) At 3 year post‐transplant
Cyclosporine patients Steroids
MMF (mg/kg/day) Tacrolimus patients
Steroids
MMF (mg/kg/day)
95 (86%)
24.4 72 (85%)
14.6 60 (69%)
20.8 40 (68%)
13.7
181 (83%)
23.5 118 (89%)
15.6 145 (73%)
21.7 80 (76%)
14.7
0.61 0.24 0.39 0.63 0.46 0.95 0.24 0.90
a
Some values missing due to incomplete reporting.
SUPPLEMENTAL DIGITAL CONTENT
SDC Table 2. Characteristics of study population for IMPDH I variant (rs2278294)
Characteristic GG n=300 GA+AA n=401 P value
Geographic origin Europe North America
270 (90%)
30 (10%)
358 (89%)
43 (11%)
0.76
Transplant year 1993‐2000 2001‐2007
129 (43%) 171 (57%)
177 (44%) 224 (56%)
0.76
Transplant number First transplant Retransplant
254 (85%)
46 (15%)
324 (81%)
77 (19%)
0.18
Recipient gender Female Male
117 (39%) 183 (61%)
155 (39%) 246 (61%)
0.93
Donor gendera Female Male
122 (41%) 178 (59%)
164 (41%) 236 (59%)
0.93
Recipient age (y) 48.6 ± 13.5 48.8 ± 13.0 0.99
Donor age (y) 47.2 ± 16.2 45.0 ± 16.4 0.047
Cold ischaemia time (h) 17.3 ± 6.3 18.7 ± 6.4 0.003
HLA‐A+B+DR mismatches
0‐1
2‐4
5‐6
34 (11%) 219 (73%)
47 (16%)
55 (14%) 293 (73%)
53 (13%)
0.47
Panel reactive antibodiesa 0‐10%
11‐50%
>50%
201 (72%)
55 (20%) 25 (9%)
264 (69%)
72 (19%) 44 (12%)
0.54
Original disease diabetes 21 (7%) 32 (8%) 0.63
Initial immunosuppression Cyclosporine
Tacrolimus
Cyclosporine patients Steroids
No steroids Tacrolimus patients
Steroids No steroids Depleting antibody Non‐depleting antibody No induction
189 (63%) 111 (37%)
184 (97%)
5 (3%) 109 (98%)
2 (2%) 32 (11%) 68 (23%) 200 (67%)
269 (67%) 132 (33%)
262 (97%)
7 (3%) 130 (98%)
2 (2%) 54 (13%) 70 (17%) 277 (69%)
0.26
0.98
0.86
0.16
Chronic immunosuppression
At 1 year post‐transplant Cyclosporine patients
Steroids
MMF (mg/kg/day) Tacrolimus patients
Steroids
MMF (mg/kg/day) At 3 year post‐transplant
Cyclosporine patients Steroids
MMF (mg/kg/day) Tacrolimus patients
Steroids
MMF (mg/kg/day)
81 (82%)
24.1 58 (82%)
13.9 54 (66%)
22.2 35 (70%)
13.3
131 (85%)
23.5 76 (88%)
15.5 104 (75%)
23.3 46 (77%)
14.4
0.49 0.7624
0.24 0.52 0.15 0.94 0.43 0.28
a
Some values missing due to incomplete reporting
SUPPLEMENTAL DIGITAL CONTENT
SDC Table 3. Characteristics of study population for IMPDH II variant (rs11706052)
Characteristic AA n=689 AG+GG n=184 P value
Geographic origin Europe North America
609 (88%) 80 (12%)
166 (90%) 18 (10%)
0.48
Transplant year 1993‐2000 2001‐2007
277 (40%) 412 (60%)
70 (38%) 114 (62%)
0.59
Transplant number First transplant Retransplant
572 (83%) 117 (17%)
158 (86%) 26 (14%)
0.35
Recipient gender Female Male
267 (39%) 422 (61%)
71 (39%) 113 (61%)
0.97
Donor gendera Female Male
278 (40%) 410 (60%)
80 (43%) 104 (57%)
0.45
Recipient age (y) 49.1 ± 13.6 48.2 ± 12.8 0.30
Donor age (y) 45.4 ± 17.0 44.6 ± 18.1 0.71
Cold ischaemia time (h) 17.9 ± 6.9 18.2 ± 7.1 0.62
HLA‐A+B+DR mismatches
0‐1
2‐4
5‐6
88 (13%) 485 (70%) 116 (17%)
22 (12%) 139 (76%)
23 (12%)
0.31
Panel reactive antibodiesa 0‐10%
11‐50%
>50%
445 (70%) 129 (20%) 63 (10%)
119 (70%)
29 (17%) 23 (13%)
0.31
Original disease diabetes 59 (9%) 12 (7%) 0.41
Initial immunosuppression Cyclosporine
Tacrolimus
Cyclosporine patients Steroids
No steroids Tacrolimus patients
Steroids No steroids Depleting antibody Non‐depleting antibody No induction
440 (64%) 249 (36%)
427 (97%)
13 (3%) 245 (98%)
4 (2%) 68 (10%) 150 (22%) 471 (68%)
116 (63%) 68 (37%)
115 (99%)
1 (1%) 68 (100%)
0 (0%) 27 (15%) 37 (20%) 120 (65%)
0.84
0.20
0.29
0.52
Chronic immunosuppression
At 1 year post‐transplant Cyclosporine patients
Steroids
MMF (mg/kg/day) Tacrolimus patients
Steroids
MMF (mg/kg/day) At 3 year post‐transplant
Cyclosporine patients Steroids
MMF (mg/kg/day) Tacrolimus patients
Steroids
MMF (mg/kg/day)
211 (83%)
23.0 136 (86%)
14.9 161 (72%)
21.6 93 (76%)
14.3
55 (86%)
24.5 36 (78%)
14.9 37 (65%)
21.7 22 (59%)
14.7
0.58 0.44 0.20 0.23 0.28 0.86 0.05 0.66
a
